Abstract
IntroductionRegorafenib was recently approved for patients with pretreated advanced colorectal cancer (aCRC), despite a moderate improvement of the patients’ outcome, and significant toxicities. Based on previous studies showing that early...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have